Iron Chelator for Solid Tumour Penetration and Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer drugs face challenges in penetrating solid tumours due to complex biophysical and metabolic conditions, leading to limited efficacy, and existing compounds do not effectively target quiescent cancer cells within 3-D tumour tissue.
Innovation Solution
A cell-permeable iron chelator compound, specifically a derivative of the general formula I, is developed to induce cytotoxic effects by reducing mitochondrial respiration and promoting apoptosis, which can be administered alone or in combination with an autophagy inhibiting agent to treat solid cancer tumours.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anticancer agents are used, then they can treat cancer cells in 2-D monolayer cultures, but they show poor penetration into 3-D tumour masses and limited efficacy against solid tumours
Solution Approach 1:
The patent employs compounds with specific molecular characteristics (formula I structures with particular pharmacophores) that exhibit enhanced penetration capabilities through 3-D tumour tissue. The chemical structure parameters are optimized to achieve both deep tissue penetration and maintained cytotoxic activity against solid tumours, resolving the contradiction between penetration depth and therapeutic efficacy.
2Quantity of substance
If anticancer drugs are administered to reach toxic concentrations in tumour parenchyme, then they must penetrate deep into 3-D tumour masses, but hypoxia and limited diffusion of nutrients lead to quiescence and resistance to conventional agents
Solution Approach 1:
The patent utilizes the unique metabolic characteristics of solid tumours, including hypoxia and altered nutrient diffusion, to enhance compound efficacy. The compounds of formula I are designed to exploit these previously harmful conditions, converting the tumour microenvironment's weaknesses into therapeutic advantages by maintaining activity against quiescent and hypoxic cells that resist conventional agents.
Solution Approach 2:
The invention changes the pharmacological parameters of the treatment by using compounds with extended spectra of activity that remain effective under hypoxic conditions and can penetrate nutrient-limited environments. This allows achieving toxic concentrations in tumour parenchyme despite the challenging biophysical barriers.
3Ease of manufacture
If 2-D monolayer cultures are used for drug screening, then the process is simple, but they do not mimic human solid tumours well and are not suitable for screening drugs active on solid tumours
Solution Approach 1:
The patent transitions from 2-D monolayer screening to 3-D multicellular spheroid models for drug evaluation. This dimensional change enables more accurate mimicry of human solid tumour architecture and physiology, allowing reliable screening of compounds like those in formula I that need to penetrate and act within 3-D tumour structures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound demonstrates significant cytotoxicity in both in-vitro and in-vivo models, particularly in multicellular spheroids, limiting cell survival to 50% or less at 10 µM/L, effectively targeting both proliferating and quiescent cancer cell populations, and increases sensitivity to glucose depletion, enhancing anti-cancer activity.
Implementation Method 1
The compound of the invention is a cell permeable iron chelator. While not wishing to bound by theory, the inventors believe that the anti-cancer effect of the compound of the invention is based on its iron-chelating properties.
Implementation Method 2
Depletion of glucose increases the sensitivity of cancer cells to the compound of the invention resulting in increased cytotoxicity and apoptosis.
Implementation Method 3
Apoptosis is mediated by the activation of caspases.
Implementation Method 4
The formation of autophagosomes is a main characteristic of autophagy. Autophagy protects cells during conditions of nutrient deprivation, and cells undergo apoptosis when autophagy is inhibited.
Implementation Method 5
The cytotoxic effect resides in the reduction of mitochondrial respiration.
Data Source
Figure 1a~1f
Figure 1g~1l
Figure 2a~2h
AI summary
In a cytotoxic compound of the general formula (I) R is H or methyl or methylene substituted by C1-C4 straight or branched alkyl, R1 is selected from the group consisting of H, C1-C4 straight or branched alkyl, methoxy, methoxy substituted by from one to three fluorine, halogen; R2 is H or C1-C4 straight or branched alkyl; X is CH or N; Y is CH or N.